[Difficult-to-treat patient with chronic hepatitis C: a challenge in clinical practice].
Dou
Xiao-guang
XG
Department of Infectious Disease, Shengjing Hospital Affiliated to China Medical University, Shenyang 110004, China. douxg@cmuzh.com
D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005838:Genotype; D019698:Hepatitis C, Chronic / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use*; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000627:therapeutic use; D012367:RNA, Viral / Q000097:blood; D012254:Ribavirin / Q000008:administration & dosage / Q000627:therapeutic use*; D019562:Viral Load
D000998:Antiviral Agents; D016898:Interferon-alpha; D012367:RNA, Viral; D011092:Polyethylene Glycols; D012254:Ribavirin